MST1 and breast carcinoma: While GAS6-mediated activation of RON has not yet been reported in breast cancer, its effects on resistance to ADT in a RON-dependent manner in prostate cancer suggests at least some overlapping function of ligand-dependent activation irrespective of whether the ligand is HGFL or GAS6.